Zhengye Biotechnology Holding Ltd ZYBT
Biotechnology: Pharmaceutical Preparations · IPO 2025 · data as of November 13, 2026
Zhengye Biotechnology Holding Ltd (ZYBT) is a healthcare company listed in the US with a market value of about $71M. In fiscal year 2025 it had revenue of $17M and net income of -$10M, a net margin of -60.0%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 40.2, a 5-year average ROIC of -8%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 93% below the current price.
About Zhengye Biotechnology Holding
Zhengye Biotechnology Holding is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2025. It was profitable in 1 of the last 2 years in our data. It spends 15% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 2 years
| Fiscal year | 2025 | 2024 |
|---|---|---|
| Revenue | $17M | $26M |
| Net income | -$10M | $2M |
| Free cash flow | $2M | $4M |
| EPS (diluted) | $-0.21 | $0.03 |
| Net margin | -60.0% | 6.1% |
| ROIC | -21.4% | 5.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Zhengye Biotechnology Holding stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 93% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Zhengye Biotechnology Holding pay a dividend?
Not currently.
Is Zhengye Biotechnology Holding a good stock to buy?
We do not give buy or sell advice. Zhengye Biotechnology Holding scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.